Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Serotonin Syndrome 1Pancreatic Neoplasms 1Carcinoid Heart Disease 1

Interventions

Gemcitabine 17Fluorouracil 8Capecitabine 6Radiotherapy 5Leucovorin 5Albumin-Bound Paclitaxel 5Taxes 4Irinotecan 4Cisplatin 4130-nm albumin-bound paclitaxel 4Specimen Handling 3Radiotherapy, Conformal 3Docetaxel 3irinotecan sucrosofate 2dehydroftorafur 2Surgical Procedures, Operative 2Radiosurgery 2Pancreaticoduodenectomy 2Chemotherapy, Adjuvant 2Cetuximab 2trametinib 1tipifarnib 1saracatinib 1pegfilgrastim 1lanreotide 1ganitumab 1durvalumab 1conatumumab 1beta-D-glucosylisophosphoramide mustard 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Pancreatic Neoplasms × lanreotide × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡